No Data
No Data
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $28
Express News | ADMA Biologics Inc : Mizuho Raises Target Price to $28 From $24
ADMA Stock Falls 19% From Its 52-Week High: Should You Buy the Dip?
Looking Into ADMA Biologics's Recent Short Interest
Can Adma Biologics (ADMA) Climb 25.5% to Reach the Level Wall Street Analysts Expect?
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating